The DSC2 Knockout Jurkat Polyclonal Cells are a targeted loss-of-function cell population generated by CRISPR/Cas9-mediated disruption of the human DSC2 gene in Jurkat T-lymphocyte cells. This polyclonal knockout product provides a heterogeneous pool of cells with genetic ablation of desmocollin-2, enabling researchers to study the impact of DSC2 deficiency without clonal selection artifacts. The product is offered as a pooled population to facilitate robust, reproducible experiments in signal transduction, cell adhesion, and immune cell biology, serving as a versatile tool for both mechanistic studies and drug discovery applications.
The host Jurkat cell line, originally derived from the peripheral blood of a 14-year-old male with acute T-cell leukemia, is a widely used human T-cell leukemia model. Jurkat cells are instrumental in dissecting T-cell receptor (TCR) signaling, apoptosis, and immune activation mechanisms. Their well-characterized signaling networks and rapid proliferation make them an ideal chassis for engineering knockout models. In this context, Jurkat cells provide a controlled background to examine the roles of desmosomal cadherins in non-epithelial cells, where canonical desmosome structures are typically absent.
DSC2 encodes desmocollin-2, a calcium-dependent cadherin of the desmosomal complex that mediates cell-cell adhesion and contributes to tissue integrity. In Jurkat cells, DSC2 knockout likely disrupts non-desmosomal cadherin functions and alters Wnt/??-catenin signaling, as DSC2 interacts with plakoglobin (JUP) and ??-catenin (CTNNB1), linking to the Wnt receptor Frizzled and LEF1/TCF transcription factors. Upstream, DSC2 is regulated by TP63 transcription factor, TGF-?? signaling, Wnt ligands such as WNT3A, calcium influx, and protein kinase C. Downstream, DSC2 absence may impair Rho GTPase (RhoA, Rac1) cytoskeletal reorganization, reduce ??-catenin/Wnt target gene transcription (e.g., MYC, CCND1), and attenuate MAPK/ERK signaling.
In the Jurkat T-lymphocyte model, DSC2 knockout holds particular significance because it allows dissection of non-canonical desmosomal gene functions in immune cells. While desmosomes are not assembled in lymphocytes, DSC2 may still influence TCR signaling, adhesion, or survival pathways through cross-talk with Wnt/??-catenin signaling. This knockout model thus provides a unique platform to interrogate whether DSC2-related pathways contribute to T-cell activation, proliferation, or apoptosis, and to explore potential roles in leukemogenesis.
Typical research applications include elucidation of DSC2 function in T-cell biology, investigation of desmosomal gene roles in leukemia, and modulation of Wnt signaling in immune cells. The cells are suitable for drug target validation for DSC2-related cancers and for modeling ARVC-associated signaling in lymphocytes. Representative assay techniques include Western blotting for DSC2 and downstream effectors (??-catenin, GSK3??), RT-qPCR for Wnt target genes (MYC, CCND1), flow cytometry for adhesion molecules, adhesion and migration assays, Wnt reporter assays (TOP/FOP flash), cell proliferation assays (MTS), and apoptosis assays (Annexin V). For further technical details, please contact Ascent Research.
